Clinical Trial

Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents

Study acronym: SORT OUT DAPT
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The SORT OUT XII dual antiplatelet treatment (DAPT) duration trial, is a clinical randomized controlled superiority and non-inferiority trial to compare whether prasugrel alone versus prasugrel plus aspirin from month 1 to month 12 after percutaneous coronary intervention with and everolimus-eluting stent in patients with acute coronary syndromes (1) is superior regarding clinically relevant bleeding and (2) non-inferior regarding safety (cardiac death, myocardial infarction, definite stent thrombosis, ischemic stroke or clinically driven target lesion revascularization)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-04.
Status change: Not Yet Recruiting → Recruiting 2025-02-26
Trial Details
NCT Number NCT06718179
Lead Sponsor Odense University Hospital
Conditions Acute Coronary Syndrome
Enrollment 3,150 participants
Start Date 2024-11-16
Primary Completion 2029-11 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-03